Drug manufacturer Eli Lilly and Co. told a court this week that HHS has placed it in the "untenable position of offering 340B discounts that are not required by the statute or else facing crippling financial sanctions." | Source: Shutterstock
Lilly Asks Court to Shield it From “Crippling” 340B Sanctions
340B program stakeholders are still digesting drug manufacturers AstraZeneca, Eli Lilly and Co., and Sanofi’s Jan. 12 lawsuits to block federal sanctions over their decisions to stop or impose conditions on 340B discounts on drugs dispensed by contract pharmacies.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
